Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

Share Price is delayed by 15 minutes
Get Live Data
13.50    0.00 (0.00%)
Bid:
13.25
Ask:
13.75
Spread: 0.50 (3.774%)
Market Cap: £65.58m
CREO Live PriceLast checked at - London Stock Exchange

Intraday Creo Medical Share Chart

Director/PDMR and PCA Share Dealings

13 Mar 2023 18:13

RNS Number : 8136S
Creo Medical Group PLC
13 March 2023
Β 

LEI: 213800H188ZDCWWXFA21

Β 

Β 

13 March 2023

Β 

Creo Medical Group plc

("Creo" or the "Company")

Β 

Director/PDMR and PCA Share Dealings

Β 

Further to the announcements made on 16 February 2023 and 8 March 2023, and pursuant to the recent fundraising, the Company confirms that each of the Company's Directors, Luis Collantes, a member of the Company's senior leadership team and a director of various of the Company's subsidiaries and certain PCAs, have either themselves or through parties affiliated with them acquired New Ordinary Shares at the Issue Price of 20 pence per Ordinary Share as follows:

Β 

Β 

Director/PDMR Name

No. of New Ordinary Shares Acquired

Resultant Shareholding post transaction

% of voting rights post transaction

Charles Spicer

165,119

308,530

0.09%

Craig Gulliford*

1,000,000

1,630,466

0.46%

Richard Rees

2,715,322

2,805,902

0.79%

Professor Christopher Hancock

383,171

4,802,352

1.36%

David Woods

415,255

440,255

0.13%

John Bradshaw

1,265,135

1,371,082

0.39%

Ivonne Cantu

125,000

125,000

0.04%

Luis Collantes**

4,442,485

4,442,485

1.27%

Β 

* These 1,000,000 shares are held by the spouse of Craig Gulliford

**Shares held via Monkey Business Consultants SL, a company owned and managed by Luis Collantes.

Β 

Β 

Creo Medical Group plc

www.creomedical.com

Richard Rees (CFO)

+44 (0)1291 606 005

Cenkos Securities plc (Nominated Adviser, Joint Bookrunner and Joint Broker)

+44 (0)20 7397 8900

Camilla Hume/Stephen Keys (NOMAD)

Russell Kerr/Michael Johnson (Sales)

Numis Securities Limited (Joint Bookrunner and Joint Broker)

Freddie Barnfield / James Black / Duncan Monteith

William Baunton (ECM)

+44 (0)20 7260 1000

Walbrook PR

Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com

Paul McManus / Sam Allen /

Phillip Marriage

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

/ +44 (0)7867 984 082Β 

Β 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Charles Spicer

2

Reason for the notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of Β£0.001 each

Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

Β£0.20

165,119

d)

Aggregated information

N/A single transaction

Aggregated volume

N/A single transaction

Price

N/A single transaction

e)

Date of the transaction

9 March 2023

f)

Place of the transaction

London Stock Exchange

Β 

Β 

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Kathryn Hogg (spouse of Craig Gulliford)

2

Reason for the notification

a)

Position/status

PCA to Craig Gulliford, Chief Executive Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of Β£0.001 each

Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

Β£0.20

1,000,000

d)

Aggregated information

N/A single transaction

Aggregated volume

N/A single transaction

Price

N/A single transaction

e)

Date of the transaction

9 March 2023

f)

Place of the transaction

London Stock Exchange

Β 

Β 

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Richard Rees

2

Reason for the notification

a)

Position/status

Chief Financial Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of Β£0.001 each

Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

Β£0.20

2,715,322

d)

Aggregated information

N/A single transaction

Aggregated volume

N/A single transaction

Price

N/A single transaction

e)

Date of the transaction

9 March 2023

f)

Place of the transaction

London Stock Exchange

Β 

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Professor Christopher Hancock

2

Reason for the notification

a)

Position/status

Chief Technology Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of Β£0.001 each

Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

Β£0.20

383,171

d)

Aggregated information

N/A single transaction

Aggregated volume

N/A single transaction

Price

N/A single transaction

e)

Date of the transaction

9 March 2023

f)

Place of the transaction

London Stock Exchange

Β 

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Woods

2

Reason for the notification

a)

Position/status

Chief Commercial Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of Β£0.001 each

Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

Β£0.20

415,255

d)

Aggregated information

N/A single transaction

Aggregated volume

N/A single transaction

Price

N/A single transaction

e)

Date of the transaction

9 March 2023

f)

Place of the transaction

London Stock Exchange

Β 

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Bradshaw

2

Reason for the notification

a)

Position/status

Independent Non-Executive Director

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of Β£0.001 each

Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

Β£0.20

1,265,135

d)

Aggregated information

N/A single transaction

Aggregated volume

N/A single transaction

Price

N/A single transaction

e)

Date of the transaction

9 March 2023

f)

Place of the transaction

London Stock Exchange

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Ivonne Cantu

2

Reason for the notification

a)

Position/status

Independent Non-Executive Director

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of Β£0.001 each

Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

Β£0.20

125,000

d)

Aggregated information

N/A single transaction

Aggregated volume

N/A single transaction

Price

N/A single transaction

e)

Date of the transaction

9 March 2023

f)

Place of the transaction

London Stock Exchange

Β 

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Luis Collantes

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Creo Medical Group plc

b)

LEI

213800H188ZDCWWXFA21

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary shares of Β£0.001 each

Identification code

GB00BZ1BLL44

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volumes(s)

Price(s)

Volume(s)

Β£0.20

4,442,485

d)

Aggregated information

N/A single transaction

Aggregated volume

N/A single transaction

Price

N/A single transaction

e)

Date of the transaction

9 March 2023

f)

Place of the transaction

London Stock Exchange

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DSHFLFLTVLIVLIV
Date   Source Headline
23rd Jun 20267:00 amRNSAppointment of Nominated Adviser /Corporate Broker
4th Jun 20267:00 amRNSPosting of 2025 Annual Report and Notice of AGM
28th May 20262:35 pmRNSHolding(s) in Company
22nd May 202610:11 amRNSResult of Placing
22nd May 20267:02 amRNSProposed Placing to raise approximately £5.5m
22nd May 20267:01 amRNSFY25 Final Results
22nd May 20267:00 amRNSProposed Sale of 49% Interest in Creo Medical SL
7th May 20267:00 amRNS-RMicroBlate™ Fine commercial update
5th May 20267:00 amRNS-RSpydrBlade™ Flex used in novel BEAM procedures
30th Apr 20267:00 amRNS-RKOL presentations on Creo Core Products at DDW
29th Apr 20267:00 amRNS-RUK private hospital use Speedboat for cancer case
22nd Apr 20267:00 amRNSPositive Q1 trading update
16th Apr 20267:00 amRNSDisposal and outsourcing of manufacturing
24th Feb 20267:00 amRNSAppointment of Joint Corporate Broker
20th Jan 20267:00 amRNSFY25 Trading Update
14th Jan 20267:00 amRNSAward of Shares under Share Incentive Plan
27th Oct 20257:00 amRNSNotice of Capital Markets Day
7th Oct 202511:37 amRNSCapital Markets Day update
22nd Sep 20257:00 amRNSUnaudited results for the six months ended 30 June
12th Sep 20253:14 pmRNSHolding(s) in Company
11th Sep 20257:00 amRNSNotice of Results
12th Aug 20254:56 pmRNSDirector/PDMR Share Dealing
4th Aug 20257:00 amRNS-RSpeedboat® patient testimonial
24th Jul 20257:00 amRNSAward of Shares under SIP and Director Dealings
21st Jul 20257:00 amRNSH1’25 Trading Update
10th Jul 20257:00 amRNS-RMicroBlate™ Flex begins lung tumour clinical study
9th Jul 20259:41 amRNSPDMR Options Revision
30th Jun 20257:00 amRNSChange of Nominated Adviser
26th Jun 202511:08 amRNSResult of AGM
26th Jun 20257:00 amRNSAGM Statement and Directorate Changes
11th Jun 20257:00 amRNS-RU.S. FDA clearance for SpydrBlade™ Flex
2nd Jun 20257:00 amRNSDirector/PDMR Shareholding
30th May 20257:00 amRNSPosting of AR&R and Notice of AGM
28th May 20257:00 amRNSUS Reimbursement milestone for Speedboat procedure
27th May 202512:48 pmRNSHolding(s) in Company
23rd May 20254:25 pmRNSHolding(s) in Company
22nd May 20257:00 amRNSDirectorate changes
19th May 20257:00 amRNSFinal Results
6th May 20257:00 amRNSNotice of investor presentations
15th Apr 20252:00 pmRNSNotice of Results
1st Apr 20259:34 amRNSHolding(s) in Company
31st Mar 202512:17 pmRNSHolding(s) in Company
26th Mar 20257:00 amRNSGrant of Options
20th Mar 20257:00 amRNS-RUK & EU Commercial launch of SpydrBlade™ Flex
6th Mar 20257:00 amRNSAppointment of Nominated Adviser and sole Broker
17th Feb 20257:00 amRNSFY24 Trading Update
12th Feb 202511:00 amRNSCompletion of sale of 51% interest in subsidiary
6th Feb 20259:00 amRNS-RFirst Welsh adopter of Speedboat® technology
3rd Feb 20253:00 pmRNSTotal Voting Rights
21st Jan 20257:00 amRNSAward of Shares under Share Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.